Recent Quotes (30 days)

You have no recent quotes
chg | %

GlaxoSmithKline plc news

   Watch this stock
Showing stories 1 - 10 of about 76   

Articles published

GSK 1,341.38 +21.88 (1.66%)
price chart
Glaxo to Begin Hostile Offer for Human Genome Sciences
May 9 (Bloomberg) -- GlaxoSmithKline Plc will begin a hostile $2.6 billion tender offer this week for Human Genome Sciences Inc. after the U.S.
GlaxoSmithKline Leads Borrowers Selling Most Debt Since March
GlaxoSmithKline Plc, the U.K.'s largest drugmaker, sold $5 billion of bonds in its first dollar-denominated offering in four years as companies market the most U.S.
Glaxo Diabetes Drug Data Revealed Amid Hostile Takeover
May 25 (Bloomberg) -- GlaxoSmithKline Plc will reveal detailed results today on an experimental treatment for diabetes that's part of the reason for a $2.6 billion hostile takeover bid for Human Genome Sciences Inc., its partner on the drug.
Glaxo's Stiefel Unit Loses $1.5 Million Verdict on Buybacks
May 18 (Bloomberg) -- Stiefel Laboratories lost a $1.5 million jury verdict to a former employee who claimed the company bought back his stock at artificially low prices before its acquisition in 2009 by GlaxoSmithKline Plc. Timothy Finnerty won the ...
GlaxoSmithKline: Complied With Indian Rules for Drug Approval
BANGALORE - GlaxoSmithKline PLC said Thursday it was granted a waiver on conducting clinical trials in India for ambrisentan, its drug to treat pulmonary arterial hypertension, as local rules allow such a concession for drugs treating a "rare disease ...
Indian drug regulator accused of malpractice  Financial Times
Indian Drug Regulator Accused of Corruption and Collusion  Bloomberg
HGSI fights GSK bid with 'poison pill'
The announcement came as the company formally rejected as “inadequate” GSK's $13 a share cash offer, which was launched last week to shareholders after it was rejected by the board.
Human Genome in Talks With Potential Suitors
May 17 (Bloomberg) -- Human Genome Sciences Inc. said it's in talks with “major” pharmaceutical and biotechnology companies about a potential transaction and adopted measures to avoid a hostile takeover by GlaxoSmithKline Plc. Human Genome ...
GlaxoSmithKline Launches Hostile Takeover Bid for Human Genome Sciences
GlaxoSmithKline Plc (NYSE: GSK), Britain's biggest drugmaker, will mount a $2.6 billion hostile takeover bid for Human Genome Sciences Inc. (NASDAQ: HGSI), the company announced Wednesday.
GSK addresses Human Genome poison pill
by Laura Board | Published May 23, 2012 at 11:04 AM GlaxoSmithKline plc Wednesday, May 23, tweaked the terms of its hostile $2.59 billion offer for Human Genome Sciences Inc. to address a poison pill mechanism its target put in place last week.
GSK requests board to drop poison pill, blocking takeover of HGS
Human Genome digs in against Glaxo
by Ben Fidler | Published May 17, 2012 at 4:44 PM DNAstrand227x128.jpg The standoff between Human Genome Sciences Inc. and GlaxoSmithKline plc escalated Thursday as the maker of lupus drug Benlysta pleaded with shareholders to shoot down the ...